GENELUX Corp (GNLX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, GENELUX reported revenue of $8,000, up 0.0% from $8,000 the year before. Net income was -$32.1M (a -401812.5% net margin), or -$0.86 per diluted share. Operating margin was -415175.0%. Operating activities generated -$25.3M of cash, leaving -$26.4M of free cash flow. At fiscal year end, GENELUX held $19.0M in total assets against $7.5M in total liabilities, including $5.3M of cash and equivalents.
Open the full interactive GENELUX financials → Quarterly statements, key ratios, valuation history and price charts.
GENELUX Key Stats
| Share Price | $2.52 |
|---|---|
| Market Cap | $113.3M |
| Revenue YoY Growth | +0.0% |
| 52-Week Range | $2.30 – $8.24 |
| Shares Outstanding | 45.0 million (basic, 2026 Q2) |
GENELUX Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $170,000 | $8,000 | $8,000 |
| Operating Income | -$24.2M | -$31.7M | -$33.2M |
| Pre-Tax Income | -$28.3M | -$29.9M | -$32.1M |
| Net Income | -$28.3M | -$29.9M | -$32.1M |
| Diluted EPS | -$1.16 | -$0.95 | -$0.86 |
GENELUX Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$8.0M | -$9.2M | -$8.9M | -$9.5M |
| Diluted EPS | -$0.21 | -$0.25 | -$0.20 | -$0.21 |
GENELUX Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $9.4M | $8.6M | $5.3M |
| Current Assets | $24.2M | $31.5M | $15.1M |
| Total Assets | $27.9M | $34.7M | $19.0M |
| Current Liabilities | $6.6M | $6.9M | $6.2M |
| Total Liabilities | $8.4M | $8.4M | $7.5M |
| Shareholders' Equity | $19.5M | $26.3M | $11.5M |
GENELUX Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$20.3M | -$21.2M | -$25.3M |
| Cash From Investing | -$14.7M | -$8.1M | $12.1M |
| Cash From Financing | $44.0M | $28.5M | $9.9M |
| Free Cash Flow | -$21.3M | -$21.6M | -$26.4M |
Figures from GENELUX's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full GENELUX financials page for every line item.
GENELUX Company Profile
| Ticker | GNLX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Westlake Village, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001231457 |
Frequently Asked Questions
What was GENELUX's revenue in fiscal 2025?
GENELUX (GNLX) reported revenue of $8,000 for fiscal 2025.
What is GENELUX's annual revenue history?
GENELUX's annual revenue by fiscal year: 2023: $170,000; 2024: $8,000; 2025: $8,000.
What was GENELUX's net income in fiscal 2025?
GENELUX reported net income of -$32.1M for fiscal 2025.
What was GENELUX's earnings per share (EPS) in fiscal 2025?
GENELUX's diluted EPS was -$0.86 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did GENELUX generate in fiscal 2025?
GENELUX generated -$26.4M of free cash flow in fiscal 2025.
How many shares of GENELUX are outstanding?
GENELUX reported a weighted average of 45.0 million basic shares outstanding in 2026 Q2.
What is GENELUX's market cap?
Based on its latest closing price, GENELUX (GNLX) has a market capitalization of about $113.3M.
When does GENELUX's fiscal year end?
GENELUX's fiscal year end, as registered with the SEC, is December 31.
Where is GENELUX headquartered?
GENELUX lists its business address in Westlake Village, California in its SEC filings.